Pulmonary Disease, Chronic Obstructive
Conditions
Brief summary
The primary objective of the trial is to show superiority in lung function of once daily (2 inhalations) treatment with orally inhaled tiotropium+olodaterol fixed dose combination to twice daily (one inhalation) treatment with fluticasone propionate+salmeterol fixed dose combination over 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). A Digital Health (DH) exploratory study has been integrated into the main study as a site specific study. The DH exploratory study will be performed at a single site; the site is also participating in the main study. The DH exploratory study site will enter (randomize) approximately 20 patients (subjects) (in addition to the patients to be enrolled in the main study at this site). The patients enrolled in the DH exploratory study are not considered to be part of the main study (i.e. data collected in the DH exploratory study will be analyzed separately from the data collected in the main study).
Interventions
DRUGTiotropium
Fixed Dose Combination
DRUGOlodaterol
Fixed Dose Combination
DRUGFluticasone propionate
Fixed Dose Combination
DRUGSalmeterol
Fixed Dose Combination
Sponsors
Boehringer Ingelheim
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* All patients must sign an informed consent consistent with FDA regulations prior to participation in the trial, which includes medication washout and restrictions. * All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria: \-- Patients with a post-bronchodilator 30% ≤ Forced Expiratory Volume in one second (FEV1) \<80% of predicted normal (European Coal and Steel Community( ECSC)); and a post-bronchodilator FEV1/Forced Vital Capacity (FVC) \<70% at Visit 1 * Male or female patients, 40 years of age or older. * Patients must be current or ex-smokers with a smoking history of more than 10 pack years. Patients who have never smoked cigarettes must be excluded. * Patients must be able to perform, according to investigator's judgment, all trial related procedures including: * Technically acceptable pulmonary function tests (spirometry) * Completion of study questionnaires * Patients must be able to inhale medication in a competent manner (in the opinion of the investigator) from the Respimat® and Diskus® inhalers and from a metered dose inhaler (MDI).
Exclusion criteria
* Patients with a significant disease other than Chronic Obstructive Pulmonary Disease (COPD); a significant disease is defined as a disease which, in the opinion of the investigator, may (i) put the patient at risk because of participation in the study, (ii) influence the results of the study, or (iii) cause concern regarding the patient's ability to participate in the study. * Patients who have had a COPD exacerbation that required treatment with antibiotics, systemic steroids (oral or intravenous) or hospitalization in the last 3 months prior to Visit 1 and/or between Visit 1 and Visit 2. * Patients with a history of asthma. For patients with allergic rhinitis or atopy, source documentation is required to verify that the patient does not have asthma. If a patient has a total blood eosinophil count ≥ 600/mm3, source documentation is required to verify that the increased eosinophil count is related to a nonasthmatic condition. Patients with any of the following conditions: * A diagnosis of thyrotoxicosis (due to the known class side effect profile of ß2-agonists). * A diagnosis of paroxysmal tachycardia (\>100 beats per minute) (due to the known class side effect profile of ß2-agonists). * A history of myocardial infarction within 1 year of screening visit (Visit 1). * Unstable or life-threatening cardiac arrhythmia. * Hospitalization for heart failure within the past year. * Known active tuberculosis. * A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years (patients with treated basal cell carcinoma are allowed). * A history of life-threatening pulmonary obstruction. * A history of cystic fibrosis. * Clinically evident bronchiectasis. * A history of significant alcohol or drug abuse. * Patients who have undergone thoracotomy with pulmonary resection (patients with a history of thoracotomy for other reasons should be evaluated as per the first exclusion criterion). * Patients being treated with oral or patch β-adrenergics. * Patients being treated with oral corticosteroid medication within 6 weeks prior to Visit 1. * Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits. * Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program. * Patients who have taken an investigational drug within one month, six half-lives or within the wash out period (whichever is greater) prior to screening visit (Visit 1). * Patients with known hypersensitivity to β-adrenergic drugs, BAC, EDTA, or any other component of the Respimat® inhalation solution. In addition, patients with known hypersensitivity to Lactose monohydrate (which contains milk proteins). * Pregnant or nursing women. * Women of childbearing potential not using a method of birth control classified at least as acceptable. Female patients will be considered to be of childbearing potential unless surgically sterilized by hysterectomy, bilateral salpingectomy, bilateral oophorectomy, or post-menopausal (defined as no menses for 12 months without an alternative medical cause). Tubal ligation is NOT a method of permanent sterilisation. * Patients who have previously been randomized in this study or are currently participating in another study. * Patients who are unable to comply with pulmonary medication restrictions prior to randomization.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment | 1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline.10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min, 12h 30 min, 13h, 14h, 22h, 23h, and 24h post morning dose at week 12. | Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 24 hours (AUC0-24) response (change from baseline) \[L\] after 12 weeks of treatment. FEV1 AUC0-24 was calculated as the area under the FEV1-time curve from 0-24 hours post-dose using the trapezoidal rule, divided by the duration (24 hours) and reported in liters. FEV1 AUC0-24 response (change from baseline) was defined as FEV1 AUC0-24 mius baseline FEV1. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment | 1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline. 10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min post morning dose at week 12. | Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 12 hours (AUC0-12) response (change from baseline) \[L\] after 12 weeks of treatment. FEV1 AUC0-12 was calculated as the area under the FEV1-time curve from 0-12 hours post-dose using the trapezoidal rule, divided by the duration (12 hours) and reported in liters. FEV1 AUC0-12 response (change from baseline) was defined as FEV1 AUC0-12 minus baseline FEV1. |
| Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | At 23 h and 24 h post dose at baseline and at 23h and 24 h post dose at week 12. | Trough Forced Expiratory Volume in one second (FEV1) response (change from baseline) \[L\] after 12 weeks treatment. Trough FEV1 was defined as the mean of the FEV1 value measured at 23 hours and at 24 hours after the trial medication administration. Through FEV1 response (change from baseline) was defined as trough FEV1 minus baseline FEV1. |
| Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | 30 minutes, 1 h, 2h and 3h post dose at baseline and week 12. | Peak 0-3 hours Forced Expiratory Volume in one second (FEV1) response (change from baseline) \[L\] after 12 weeks treatment. Peak 0-3h was defined as the maximum value measured within the first three hours post doing. |
Countries
United States
Participant flow
Recruitment details
The study compares treatment tiotropium+olodaterol (5μg/5μg) once daily FDC to Fluticasone propionate+Salmeterol (250μg/50μg) twice daily FDC over 12 weeks in patients with COPD. A Digital Health (DH)-study has been integrated a site specific study. The patients enrolled in the DH-study are not considered to be part of the main study.
Pre-assignment details
All subjects were screened for eligibility prior to participation in the trial. Subjects attended a specialist site which ensured that they (the subjects) strictly met all inclusion and non of the exclusion criteria. Subjects were not to be allocated to a treatment group if any of the entry criteria were violated.
Participants by arm
| Arm | Count |
|---|---|
| Tiotropium+Olodaterol (5μg/5μg) - Main Study 2 inhalations of fixed dose combination (FDC) of 2.5 microgram (μg) tiotropium and 2.5μg olodaterol (T+O) (total 5μg/5μg) were administered orally once daily in the morning via RESPIMAT inhaler over a treatment period of 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). Patients enrolled in the main study were not eligible to participate in the DH study. | 146 |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study 2 inhalations of fixed dose combination (FDC) of 250μg fluticasone propionate and 50μg salmeterol (F+S) (total 500μg/100μg) were administered orally twice daily in the morning and in the evening (12h after morning dose) via Diskus inhaler over a treatment period of 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). Patients enrolled in the main study were not eligible to participate in the DH study. | 145 |
| Tiotropium+Olodaterol (5μg/5μg) - DH-study 2 inhalations of fixed dose combination (FDC) of 2.5 microgram (μg) tiotropium and 2.5μg olodaterol (T+O) (total 5μg/5μg) were administered orally once daily in the morning via RESPIMAT inhaler over a treatment period of 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). Patients enrolled in the DH study were not eligible to participate in the main study. | 6 |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - DH-study 2 inhalations of fixed dose combination (FDC) of 250μg fluticasone propionate and 50μg salmeterol (F+S) (total 500μg/100μg) were administered orally twice daily in the morning and in the evening (12h after morning dose) via Diskus inhaler over a treatment period of 12 weeks in patients with Chronic Obstructive Pulmonary Disease (COPD). Patients enrolled in the DH study were not eligible to participate in the main study. | 5 |
| Total | 302 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Adverse Event | 0 | 2 | 0 | 1 |
| Overall Study | Other | 0 | 1 | 0 | 0 |
| Overall Study | Withdrawal by Subject | 2 | 11 | 0 | 1 |
Baseline characteristics
| Characteristic | Tiotropium+Olodaterol (5μg/5μg) - Main Study | Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study | Tiotropium+Olodaterol (5μg/5μg) - DH-study | Fluticasone Propionate+Salmeterol (500μg/100μg) - DH-study | Total |
|---|---|---|---|---|---|
| Age, Continuous | 63.95 years STANDARD_DEVIATION 8.32 | 64.74 years STANDARD_DEVIATION 7.33 | 71.00 years STANDARD_DEVIATION 4.77 | 60.00 years STANDARD_DEVIATION 4.58 | 63.44 years STANDARD_DEVIATION 7.81 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 2 Participants | 2 Participants | 0 Participants | 0 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 144 Participants | 143 Participants | 6 Participants | 5 Participants | 298 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) Black or African American | 14 Participants | 16 Participants | 0 Participants | 0 Participants | 30 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 1 Participants | 0 Participants | 0 Participants | 1 Participants |
| Race (NIH/OMB) White | 132 Participants | 127 Participants | 6 Participants | 5 Participants | 270 Participants |
| Sex: Female, Male Female | 72 Participants | 62 Participants | 1 Participants | 4 Participants | 139 Participants |
| Sex: Female, Male Male | 74 Participants | 83 Participants | 5 Participants | 1 Participants | 163 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 152 | 0 / 150 |
| other Total, other adverse events | 8 / 152 | 15 / 150 |
| serious Total, serious adverse events | 6 / 152 | 3 / 150 |
Outcome results
Primary
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment
Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 24 hours (AUC0-24) response (change from baseline) \[L\] after 12 weeks of treatment. FEV1 AUC0-24 was calculated as the area under the FEV1-time curve from 0-24 hours post-dose using the trapezoidal rule, divided by the duration (24 hours) and reported in liters. FEV1 AUC0-24 response (change from baseline) was defined as FEV1 AUC0-24 mius baseline FEV1.
Time frame: 1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline.10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min, 12h 30 min, 13h, 14h, 22h, 23h, and 24h post morning dose at week 12.
Population: Full Analysis Set (FAS): FAS included all patients in the TS who had baseline and at least one post-baseline measurement for at least one efficacy parameter. The Mixed-effects model repeated measurement (MMRM) model defined the participants who contributed to the model.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tiotropium+Olodaterol (5μg/5μg) - Main Study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment | 0.174 Litre*hours (L*h) | Standard Error 0.019 |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment | 0.122 Litre*hours (L*h) | Standard Error 0.019 |
| Tiotropium+Olodaterol (5μg/5μg) - DH-study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment | NA Litre*hours (L*h) | — |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - DH-study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 24 Hours (AUC0-24) Response (Change From Baseline) [L] After 12 Weeks of Treatment | NA Litre*hours (L*h) | — |
p-value: 0.054395% CI: [-0.001, 0.105]Mixed-effects model repeated measures
Secondary
Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment
Forced Expiratory Volume in one second (FEV1) Area under the Curve from 0 to 12 hours (AUC0-12) response (change from baseline) \[L\] after 12 weeks of treatment. FEV1 AUC0-12 was calculated as the area under the FEV1-time curve from 0-12 hours post-dose using the trapezoidal rule, divided by the duration (12 hours) and reported in liters. FEV1 AUC0-12 response (change from baseline) was defined as FEV1 AUC0-12 minus baseline FEV1.
Time frame: 1 hours (h) and 10 minutes (min) before first dose at day1 of weeks 1 for baseline. 10 min before and 30 min, 1 h, 2h, 3h, 4h, 6h, 8h, 10h, 11h 50min post morning dose at week 12.
Population: Full Analysis Set (FAS): FAS included all patients in the TS who had baseline and at least one post-baseline measurement for at least one efficacy parameter. The Mixed-effects model repeated measurement (MMRM) model defined the participants who contributed to the model.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tiotropium+Olodaterol (5μg/5μg) - Main Study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment | 0.237 Litre*hours (L*h) | Standard Error 0.019 |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment | 0.147 Litre*hours (L*h) | Standard Error 0.02 |
| Tiotropium+Olodaterol (5μg/5μg) - DH-study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment | NA Litre*hours (L*h) | — |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - DH-study | Forced Expiratory Volume in One Second (FEV1) Area Under the Curve From 0 to 12 Hours (AUC0-12) Response (Change From Baseline) [L] After 12 Weeks of Treatment | NA Litre*hours (L*h) | — |
p-value: 0.001195% CI: [0.037, 0.144]Mixed-effects model repeated measures
Secondary
Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment
Peak 0-3 hours Forced Expiratory Volume in one second (FEV1) response (change from baseline) \[L\] after 12 weeks treatment. Peak 0-3h was defined as the maximum value measured within the first three hours post doing.
Time frame: 30 minutes, 1 h, 2h and 3h post dose at baseline and week 12.
Population: Full Analysis Set (FAS): FAS included all patients in the TS who had baseline and at least one post-baseline measurement for at least one efficacy parameter. The Mixed-effects model repeated measurement (MMRM) model defined the participants who contributed to the model.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tiotropium+Olodaterol (5μg/5μg) - Main Study | Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | 0.341 Litre (L) | Standard Error 0.021 |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study | Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | 0.243 Litre (L) | Standard Error 0.021 |
| Tiotropium+Olodaterol (5μg/5μg) - DH-study | Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | NA Litre (L) | — |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - DH-study | Peak 0-3 Hours Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | NA Litre (L) | — |
p-value: 0.00195% CI: [0.04, 0.156]Mixed-effects model repeated measures
Secondary
Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment
Trough Forced Expiratory Volume in one second (FEV1) response (change from baseline) \[L\] after 12 weeks treatment. Trough FEV1 was defined as the mean of the FEV1 value measured at 23 hours and at 24 hours after the trial medication administration. Through FEV1 response (change from baseline) was defined as trough FEV1 minus baseline FEV1.
Time frame: At 23 h and 24 h post dose at baseline and at 23h and 24 h post dose at week 12.
Population: Full Analysis Set (FAS): FAS included all patients in the TS who had baseline and at least one post-baseline measurement for at least one efficacy parameter. The Mixed-effects model repeated measurement (MMRM) model defined the participants who contributed to the model.
| Arm | Measure | Value (MEAN) | Dispersion |
|---|---|---|---|
| Tiotropium+Olodaterol (5μg/5μg) - Main Study | Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | 0.118 Litre (L) | Standard Error 0.019 |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - Main Study | Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | 0.114 Litre (L) | Standard Error 0.019 |
| Tiotropium+Olodaterol (5μg/5μg) - DH-study | Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | NA Litre (L) | — |
| Fluticasone Propionate+Salmeterol (500μg/100μg) - DH-study | Trough Forced Expiratory Volume in One Second (FEV1) Response (Change From Baseline) [L] After 12 Weeks Treatment | NA Litre (L) | — |
p-value: 0.859395% CI: [-0.048, 0.058]Mixed-effects model repeated measures